PLUS THERAPEUTICS
Plus Therapeutics is dedicated to developing and delivering innovative cell-based therapies to improve the quality and length of life. It is a global, public company engaged in developing and commercializing stem and regenerative cell therapies for treating cardiovascular disease, reconstructive surgery, and other serious, chronic, and life-threatening conditions. The company's research and development efforts are developing novel formulations and delivery methods for existing drugs to improve t... heir efficacy and reduce side effects. Plus Therapeutics utilizes its proprietary nanotechnology platform to enhance the therapeutic potential of drugs, allowing for targeted delivery to tumors while minimizing damage to healthy tissues. Their pipeline includes potential treatments for various types of cancer, including brain cancer and pancreatic cancer. Plus Therapeutics' pipeline of candidate drug products includes their lead drug product candidates, RNL and DocePLUS, which are being developed in the U.S. by a dedicated and energetic team of biologists, chemists, engineers, physicians, and other professionals.
PLUS THERAPEUTICS
Industry:
Biotechnology Medical Pharmaceutical Therapeutics
Founded:
1996-01-01
Address:
Austin, Texas, United States
Country:
United States
Website Url:
http://www.plustherapeutics.com
Total Employee:
11+
Status:
Active
Contact:
737.255.7194
Email Addresses:
[email protected]
Total Funding:
152.25 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Domain Not Resolving Euro Google Font API WordPress Google Analytics Content Delivery Network Mobile Non Scaleable Content Organization Schema
Similar Organizations
Arctic Therapeutics
Arctic Therapeutics (AT) uses bioinformatic approaches and AI to eliminate major risks associated with traditional drug development.
Aro Biotherapeutics
Aro Biotherapeutics develops tissue-targeted genetic medicines using Centyrins, a proprietary technology, to address complex diseases.
Avstera Therapeutics
Avstera Therapeutics is an oncology-focused biotech company that fulfil unmet needs of cancer patients.
Eden Biologics
Eden Biologics is a biopharmaceutical company that develops biosimilars and accelerates the development programs for clients & partners.
Navrogen
Navrogen is a biopharmaceutical company focused on the targeted treatment of cancer.
PhaseBio Pharmaceuticals
PhaseBio is a clinical-stage biopharmaceutical company that develops drugs for cardiovascular diseases, endocrine, and metabolic disorders.
Pinpoint Therapeutics
Pinpoint Therapeutics is a preclinical stage company developing novel cancer treatment options aimed to specifically inhibit autophagy.
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
Spark Therapeutics
Spark Therapeutics is focused on the development of gene therapy.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2017-02-15 | Azaya Therapeutics | Azaya Therapeutics acquired by Plus Therapeutics | N/A |
Investors List
AIGH Capital Management
AIGH Capital Management investment in Post-IPO Equity - Plus Therapeutics
U.S. Department of Defense
U.S. Department of Defense investment in Grant - Plus Therapeutics
Cancer Prevention and Research Institute of Texas
Cancer Prevention and Research Institute of Texas investment in Grant - Plus Therapeutics
GE Capital
GE Capital investment in Post-IPO Debt - Plus Therapeutics
Oxford Finance LLC
Oxford Finance LLC investment in Post-IPO Debt - Plus Therapeutics
Silicon Valley Bank
Silicon Valley Bank investment in Post-IPO Debt - Plus Therapeutics
Official Site Inspections
http://www.plustherapeutics.com Semrush global rank: 5.05 M Semrush visits lastest month: 1.61 K
- Host name: 141.193.213.20
- IP address: 141.193.213.20
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Plus Therapeutics"
Plus Therapeutics - Wikipedia
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for adults and children with rare and difficult-to-treat cancers. The …See details»
Press Releases - Plus Therapeutics Inc.
Apr 23, 2025 The Investor Relations website contains information about Plus Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.See details»
Plus Therapeutics - Crunchbase Company Profile
Plus Therapeutics is a clinical-stage pharmaceutical company that develops targeted therapies to treat cancer and other serious diseases.See details»
Plus Therapeutics - News, Mergers and Acquisitions ... - Usearch
Usearch identified 5 signals for Plus Therapeutics, including: 2 Startup Funding, 2 Partnerships and 1 Mergers and Acquisitions. Usearch discovered 1 location for Plus Therapeutics …See details»
PLUS THERAPEUTICS - 2025 Company Profile - Tracxn
May 24, 2025 PLUS THERAPEUTICS - Provider of therapeutics for multiple cancer treatments. Public Company. Raised funding over 5 rounds from 3 investors.See details»
Plus Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...
Explore Plus Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 5 clinical trials, 138 news, and 29 literature, Disease Domain ...See details»
Our Team - Plus Therapeutics (PSTV)
No matter our role, our employees share equal dedication to solving the most difficult challenges in cancer treatment through novel radiotherapeutics.See details»
Plus Therapeutics to Provide Business Update and Host
3 days ago Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, June 26, 2025 at 9:00 A.M. ET June 25, 2025 16:15 ET | Source: Plus Therapeutics …See details»
Plus Therapeutics to Provide Business Update and Host …
2 days ago HOUSTON, June 25, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing …See details»
Our Platform - Plus Therapeutics (PSTV)
However, with traditional approaches in radiation therapy, safely delivering high radiation doses to a single target region and keeping it there long enough to completely eliminate the tumor has …See details»
Plus Therapeutics Enters Into Master Services Agreement
Mar 23, 2021 Plus Therapeutics Enters Into Master Services Agreement with Piramal Pharma Solutions, a Leading Contract Development and Manufacturing Organization Agreement …See details»
About Radiotherapeutics - Plus Therapeutics (PSTV)
In recent years, radiotherapeutics have been developed as a way to deliver radiation therapy directly and specifically to cancer cells. An explosion of new studies shows the potential of …See details»
Plus Therapeutics Reports Fourth Quarter and Full Year 2024 …
Mar 27, 2025 The recent $15 million financing accelerates development of REYOBIQ™ and launch of CNSide™ HOUSTON, March 27, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, …See details»
Plus Therapeutics (PSTV) - Home
Plus Therapeutics is focused on developing innovative, targeted radiotherapeutics for adults & children with difficult-to-treat cancer. Leveraging novel drug formulations and technologies, our …See details»
Plus Therapeutics Announces Comprehensive Restructuring of $15 …
5 days ago Comprehensive restructuring eliminates the potential issuance of up to 1.5 billion shares of common stock Plus Therapeutics files a request to withdraw the related resale …See details»
Pipeline - Plus Therapeutics (PSTV)
A promising suite of precision radiotherapeutics. Leveraging novel drug formulations, we have developed a radiotherapeutic platform with the potential to lengthen and improve the lives of …See details»
Plus Therapeutics Provides Business Update on CNSide …
3 days ago For more information, visit https://www.plustherapeutics.com. Forward-Looking Statements This press release contains statements that may be deemed “forward-looking …See details»
Management - Plus Therapeutics (PSTV)
Michael Rosol Dr. Rosol has 25 years of experience in preclinical and clinical research, trial design, operations, and regulatory execution. Most recently, he served as Chief Executive …See details»
ir.plustherapeutics.com
Ir.plustherapeutics.comSee details»
Plus Therapeutics Restructures Financing to Eliminate ... - Nasdaq
4 days ago Plus Therapeutics restructures equity financing, eliminating potential dilution and enhancing shareholder value, while withdrawing associated SEC registration.See details»